Clinical Trials Sponsored by Armata Pharmaceuticals, Inc.

Total 4978 results

Coordination Pharmaceuticals, Inc.

Recruiting

Phase I Study of RiMO-401 With Radiation in Advanced Tumors

Advanced Solid Tumor | Intratumoral Injection

United States
LB Pharmaceuticals Inc.

Recruiting

Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

Schizophrenia

United States
Alexion Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults

Healthy

United Kingdom
ACADIA Pharmaceuticals Inc.

Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United States
A2A Pharmaceuticals Inc.

Recruiting

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors

Triple Negative Breast Cancer | Endometrial Cancer | High Grade Serous Ovarian Cancer

United States
Rocket Pharmaceuticals Inc.

Recruiting

A Multi-Center, Open Label Gene Therapy Study of RP-A501 in Male Patients With Danon Disease

Danon Disease

United States
Alexion Pharmaceuticals, Inc.

Not yet recruiting

Phase 3 Study of ALXN1850 in Treatment-Naïve Pediatric Participants With HPP (MULBERRY)

Hypophosphatasia

United States, Taiwan, Thailand, Vietnam, United Kingdom, Korea, Republic of, Israel, Italy, Australia, Turkey, France, Poland, Germany, Spain, Belgium, China, Canada, Brazil, Argentina, Mexico
Alexion Pharmaceuticals, Inc.

Recruiting

Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa (HICKORY)

Hypophosphatasia

Italy, Spain, Israel, Korea, Republic of, Belgium, Germany, United States, China, France, Taiwan, Austria, Japan, India, Australia, Argentina, Poland, Turkey, Brazil, Thailand, United Kingdom, Canada, Slovakia, Czechia
Olema Pharmaceuticals, Inc.

Recruiting

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast Cancer

United States, Korea, Republic of, Australia, Hong Kong, Taiwan, Malaysia, Thailand, Argentina, Belgium, Portugal
Recursion Pharmaceuticals Inc.

Recruiting

A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation

Solid Tumor | APC Gene Mutation | AXIN1 Gene Mutation

United States
Crinetics Pharmaceuticals Inc.

Recruiting

Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)

Congenital Adrenal Hyperplasia | Classic Congenital Adrenal Hyperplasia

Brazil, India, United States, Argentina, Italy, United Kingdom
Cascade Pharmaceuticals, Inc

Recruiting

CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)

Primary Biliary Cholangitis (PBC)

China
Cascade Pharmaceuticals, Inc

Recruiting

CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis)

Primary Sclerosing Cholangitis

China
Sermonix Pharmaceuticals Inc.

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Metastatic Breast Cancer

United States, France, Belgium, Spain, Israel, Taiwan, United Kingdom, Korea, Republic of, Italy, Australia, Germany, Canada, Czechia, Hungary, Poland, Romania, Singapore, Turkey
Fusion Pharmaceuticals Inc.

Recruiting

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

Gastric Cancer | Colorectal Cancer | Ewing Sarcoma | Squamous Cell Carcinoma of Head and Neck | Pancreatic Ductal Adenocarcinoma (PDAC) | NTSR1 Expressing Solid Tumours | Neuroendocrine Differentiated (NED) Prostate Cancer

United States, Australia
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Hungary, Poland, Italy
Escient Pharmaceuticals, Inc

Recruiting

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis (PACIFIC)

Pruritus

United States, United Kingdom, Belgium, Israel, Spain, Canada, France, Netherlands
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

Hereditary Angioedema

United States, Puerto Rico, Belgium, Bulgaria, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Turkey, United Kingdom
Regor Pharmaceuticals Inc.

Recruiting

First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Breast Cancer

United States
Xynomic Pharmaceuticals, Inc.

Not yet recruiting

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Melanoma | Cancer | Colorectal Cancer | Nonsmall Cell Lung Cancer | Thyroid Cancer | BRAF V600 Mutation
Fusion Pharmaceuticals Inc.

Recruiting

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST)

Metastatic Castration Resistant Prostate Cancer

United States
EyePoint Pharmaceuticals, Inc.

Recruiting

Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract

Cataract

United States
Tasly Pharmaceuticals, Inc.

Not yet recruiting

Evaluate the Efficacy, Safety and Tolerability of TSUPPORT for Adults With Tourette Syndrome

Tourette Syndrome

United States
Rhythm Pharmaceuticals, Inc.

Recruiting

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

Obesity | Genetic Obesity

United States, Spain, Germany, Netherlands, United Kingdom, Greece, Puerto Rico, Canada, France, Israel
Ionis Pharmaceuticals, Inc.

Recruiting

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

Severe Hypertriglyceridemia

United States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
Ionis Pharmaceuticals, Inc.

Recruiting

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

United States, Italy, Portugal, Spain, Taiwan, Sweden, Canada, Brazil, France, New Zealand, Argentina, Cyprus, Australia, Turkey
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
Tasly Pharmaceuticals, Inc.

Recruiting

Safety and Efficacy of T89 in the Prevention and Treatment of Adults With Acute Mountain Sickness (AMS)

Acute Mountain Sickness (AMS)

United States, China
Generian Pharmaceuticals, Inc.

Not yet recruiting

A Phase I Study of GT300 in Healthy Subjects

Lewy Body Disease
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Astex Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

Acute Myeloid Leukemia | Myelodysplastic Syndromes

Spain, Poland, Bulgaria, Lithuania, Slovakia, Romania
Allist Pharmaceuticals, Inc.

Recruiting

Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)

NSCLC

China
Allist Pharmaceuticals, Inc.

Not yet recruiting

To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (FORWARD)

Non-small Cell Lung Carcinoma
Faraday Pharmaceuticals, Inc.

Recruiting

Evaluation in STEMI Patients Using FDY-5301 (IOCYTE AMI-3)

Acute Myocardial Infarction | STEMI | Percutaneous Coronary Revascularization

United States, Israel, Poland, Portugal, Hungary, Canada
Mirum Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VISTAS)

Primary Sclerosing Cholangitis

United States, United Kingdom, Israel, Germany, Canada
Spectrum Pharmaceuticals, Inc

Recruiting

A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy

Lymphoma | Solid Tumors

United States
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Pediatric Participants With HSCT-TMA

Thrombotic Microangiopathy

United States, France, Israel, Italy, Japan, Korea, Republic of, Spain, United Kingdom, Germany
Alexion Pharmaceuticals, Inc.

Recruiting

Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

Thrombotic Microangiopathy

United States, Italy, Spain, Korea, Republic of, United Kingdom, Belgium, Netherlands, Germany, Japan, Greece, Brazil, Israel, France, China, Sweden, Australia, Canada, Poland
SFJ Pharmaceuticals, Inc.

Recruiting

Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT)

Hemorrhage | Invasive Procedure | Urgent Surgery

United States, Netherlands, China, Sweden, Austria, Belgium, France, Italy, Spain, Switzerland, United Kingdom, Canada, Germany
Ionis Pharmaceuticals, Inc.

Recruiting

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ION464 Administered to Adults With Multiple System Atrophy (HORIZON) (HORIZON)

Multiple System Atrophy

Austria, Portugal, France, Germany, United Kingdom
Supernus Pharmaceuticals, Inc.

Recruiting

Therapy for Migraine Prevention in Children 6-11 Years of Age

Migraine Disorders | Headache Disorders

United States
AMAG Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects

Iron Deficiency Anemia

United States, Lithuania, Poland
Xynomic Pharmaceuticals, Inc.

Recruiting

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Renal Cell Carcinoma

China, Spain, United States, Italy, Korea, Republic of, Poland
Aragon Pharmaceuticals, Inc.

Recruiting

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

Moldova, Republic of, Spain
Alkeus Pharmaceuticals, Inc.

Recruiting

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Stargardt Disease | Stargardt Macular Degeneration | Stargardt Macular Dystrophy | Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

United States
Aegerion Pharmaceuticals, Inc.

Recruiting

MEASuRE: Metreleptin Effectiveness And Safety Registry (MEASuRE)

Partial Lipodystrophy | Generalised Lipodystrophy

United States, Germany, Italy
Alexion Pharmaceuticals, Inc.

Recruiting

Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry

Paroxysmal Nocturnal Hemoglobinuria

United States
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia

Cardiovascular Diseases | Atherosclerosis | Hypertriglyceridemia

United States, Spain, Italy, Denmark, Hungary, Netherlands, Canada, France, Poland, Bulgaria, Czechia, Portugal, Slovakia, Norway
Ionis Pharmaceuticals, Inc.

Active, not recruiting

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)

Familial Chylomicronemia Syndrome

Spain, United Kingdom, France, Canada, United States, Italy, Netherlands, Norway, Portugal, Slovakia, Sweden
Astex Pharmaceuticals, Inc.

Active, not recruiting

A Study of TAS1440 With ATRA in Subjects With r/r AML

Acute Myeloid Leukemia

United States

Clinical Trials Sponsored by Armata Pharmaceuticals, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations